Navigation Links
Newly Published Acetadote(R) Data Shows Product Can Provide Substantial Cost-Savings for Healthcare Systems
Date:12/1/2009

NASHVILLE, Tenn., Dec. 1 /PRNewswire-FirstCall/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) announced today that an independently conducted study of Acetadote (acetylcysteine) Injection, or intravenous N-acetylcysteine, as a cost-saving treatment for acetaminophen poisoning was published in Volume 12, Number 4 of the peer-reviewed Journal of Medical Economics, distributed in December. The study concludes that Acetadote is a less costly treatment regimen than oral N-acetylcysteine in all evaluated scenarios.

The cost differential between the use of oral N-acetylcysteine and Acetadote was shown to range between $881 and $2,259 depending on the time elapsed since ingestion and the decision to manage patients in the intensive care unit (ICU) or the general ward.

"The results of this analysis provide a strong economic argument for treatment of acetaminophen poisoning with Acetadote for substantial cost savings to the healthcare system," said Dr. Albert Marchetti, President and Medical Director of the Medical Education and Research Alliance of America, Adjunct Professor at the University of Medicine and Dentistry of New Jersey, and lead author of the publication. "Using real world data to model best- and worst-case scenarios, Acetadote was shown to be the less costly option in all cases."

A principal difference between oral N-acetylcysteine and Acetadote administration is the time required to complete recommended treatment. Under approved therapeutic protocols, the oral product requires 72 hours to administer compared to 21 hours for Acetadote. Consequently, the use of Acetadote results in shorter hospital stays, which is the primary reason for the substantial cost disparity between the two treatments.

To provide assistance in evaluating potential savings for individual ho
'/>"/>

SOURCE Cumberland Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
2. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
3. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
4. Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
5. New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma
6. Newly Approved HIV Drug Shows Great Promise
7. New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma
8. VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma
9. Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma
10. Newly Published Study Shows OPKOs siRNA Bevasiranib Is Taken Up by Target Tissues in the Eye
11. Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... WAYNE, Pa. , July 1, 2015 /PRNewswire/ ... a fully integrated specialty pharmaceutical company focused on ... announced that Bob Radie , president and ... upcoming conferences this summer. He will provide an ... (ketorolac tromethamine) Nasal Spray, approved product ...
(Date:7/1/2015)... 2015 New exchange plan enrollees spent less ... to the same time a year ago, according to ... ESRX ) Exchange Pulse™ report, released today. ... number of new exchange plan enrollees who used at ... first quarter of 2015. However, when evaluating exchange plan ...
(Date:7/1/2015)... July 1, 2015 The Haselmeier ... Board. Mr. Gert Weber has been nominated ... as Chief Executive Officer (CEO) of the ... st , 2015. Mr. Weber brings more than 20 ... and has filled various executive management positions, the last ...
Breaking Medicine Technology:Egalet to Present at Upcoming Conferences This Summer 2Egalet to Present at Upcoming Conferences This Summer 3Express Scripts Provides First Look at 2015 Public Exchange Pharmacy Trends 2Express Scripts Provides First Look at 2015 Public Exchange Pharmacy Trends 3Express Scripts Provides First Look at 2015 Public Exchange Pharmacy Trends 4Express Scripts Provides First Look at 2015 Public Exchange Pharmacy Trends 5Haselmeier Group Announces the Extension and Reorganization of its Executive Board 2
... HOUSTON, Nov. 11 The Houston trial law firm ... the makers of pain pumps and related medications based on claims ... are causing irreversible shoulder damage among patients. , Currently, the attorneys ... people who received pain pumps to manage pain following shoulder surgery. ...
... 11 The Endovascular Forum (EVF), an IC Sciences company, ... and Technologies (GEST), and the launch of a dynamic online ... with the GEST mission and aim of bringing practitioners the ... of new materials and devices, their results, relevance for patient ...
Cached Medicine Technology:Arnold & Itkin Announces Lawsuits Over Defective Pain Pumps 2Arnold & Itkin Announces Lawsuits Over Defective Pain Pumps 3Endovascular Forum and GEST Set Out on a Shared Venture to Bring the Highest Level of Embolization-based Scientific and Technical Education, Results, and Relevance for Patient Care 2Endovascular Forum and GEST Set Out on a Shared Venture to Bring the Highest Level of Embolization-based Scientific and Technical Education, Results, and Relevance for Patient Care 3
(Date:7/1/2015)... Tokyo, Japan (PRWEB) , ... July 01, 2015 ... ... August 2015 of a new extraction plant for Linablue®, Spirulina-derived natural blue food ... Earthrise Nutritionals, LLC, the DIC Group’s U.S. Spirulina* production base, began in May ...
(Date:7/1/2015)... ... July 01, 2015 , ... Summer recess has a ... to fix noses and chins with plastic surgery when they’re looking for a boost ... than 236,000 cosmetic procedures were performed on patients ages 19 and younger in 2012, ...
(Date:7/1/2015)... (PRWEB) , ... July 01, 2015 , ... As if ... symptom found in a significant number of women: leg pain. Northeast Houston Vein Center ... Leg pain, a symptom of venous reflux disease, is underdiagnosed and often overlooked. Many ...
(Date:7/1/2015)... (PRWEB) , ... July 01, 2015 , ... Scoliosis is a disorder in which the ... Scoliosis Foundation, it affects 2 to 3 percent of the population, or an estimated 6 ... often develops in children between the ages of 10 and 15. Most types of scoliosis ...
(Date:7/1/2015)... ... July 01, 2015 , ... Bunion Bootie, the ... Customers purchasing two or more Bunion Booties directly from their website, http://www.BunionBootie.com ... temporarily corrects misaligned toes and its ultra thin properties allow for protection against ...
Breaking Medicine News(10 mins):Health News:DIC Strengthens Its Position as the Global Leader for Natural Blue Food Coloring 2Health News:DIC Strengthens Its Position as the Global Leader for Natural Blue Food Coloring 3Health News:Top Manhattan Facial Plastic Surgeon Dr. Sam Rizk Comments on Teen Surgery Trends 2Health News:Top Manhattan Facial Plastic Surgeon Dr. Sam Rizk Comments on Teen Surgery Trends 3Health News:Northeast Houston Vein Center Offers Tips for Women with Leg Pain 2Health News:Northeast Houston Vein Center Offers Tips for Women with Leg Pain 3Health News:Scoliosis: A Guide for Parents from Orthopedic Surgeon Dr. Fabien Bitan 2Health News:Scoliosis: A Guide for Parents from Orthopedic Surgeon Dr. Fabien Bitan 3Health News:Scoliosis: A Guide for Parents from Orthopedic Surgeon Dr. Fabien Bitan 4Health News:Bunion Bootie, the #1 Non-Surgical Treatment for Bunion Pain, Announces Their Big Summer Sale 2
... SCHAUMBURG, Ill. , Jan. 20 The American ... joined a coalition of other animal health and welfare groups to ... following the January 12 earthquake that devastated the country. ... was developed by the International Fund for Animal Welfare (IFAW) and ...
... found that acyclovir, a drug widely used as a safe ... virus-2 (HSV-2), which is the most common cause of genital ... taken by people infected with both HIV and HSV-2. ... New England Journal of Medicine online today, and will ...
... NJ A new brain-based computational model is ... medicationsused to treat motor symptoms caused by the ... reported in a forthcoming article in the ... a new computational model, developed by Drs. Ahmed ...
... injections could boost treatment, experts say, but safety concerns ... new drugs -- both oral, rather than injected -- may ... all being published early online Jan. 20 in the ... drugs -- fingolimod and cladribine -- reduce relapse rates in ...
... , Jan. 20 Family Research Council ( ... the following statement regarding the Massachusetts Senate election results: ... to be in the left-hand column into eternity, the results of ... visit to the Bay State made it clear that ...
... recent years, there has been a large increase in the ... approximately 51% of non-pregnant women ages 20 to 39 being ... in the journal Nursing for Women,s Health finds ... birth defects, as well as a greater risk of childhood ...
Cached Medicine News:Health News:U.S. Veterinarians Join Coalition to Help Haiti 2Health News:U.S. Veterinarians Join Coalition to Help Haiti 3Health News:Herpes medication does not reduce risk of HIV transmission, UW-led international study finds 2Health News:Herpes medication does not reduce risk of HIV transmission, UW-led international study finds 3Health News:Herpes medication does not reduce risk of HIV transmission, UW-led international study finds 4Health News:A novel computational model -- how Parkinson's medications affect learning and attention 2Health News:First Oral Medications For MS Show Promise 2Health News:First Oral Medications For MS Show Promise 3Health News:FRC: Mass Election Results a Near Revolutionary Rejection of President Obama's Leftist Agenda 2Health News:Pregnant women who are overweight put their infants at risk 2
Porous foundation 440 series....
Exactech's AcuMatch C-Series (cemented femoral stem) is designed to provide solutions to the problems which compromise both the short and long term successful outcome of cemented hip arthroplasty....
The Biopro optima stem is manufactured from cobalt chrome and is available in a Non-Porous coat option....
The cemented hip joint prosthesis system....
Medicine Products: